Latest Breaking News On - Shire international licensing - Page 1 : comparemela.com

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress - Unicycive Therapeutics (NASDAQ:UNCY)

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress - Unicycive Therapeutics (NASDAQ:UNCY)
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSatya medicherlaShalabh guptaEuropean renal associationShire international licensingUnicycive therapeutics incReason researchExchange commissionCompany or unicyciveMoral administrationDrug administrationRenal associatesPreclinical modelHyperphosphatemia demonstrateRelative potency

Unicycive Therapeutics Presents Bioequivalence Data on

Unicycive Therapeutics Presents Bioequivalence Data on
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesVandana mathurShalabh guptaReason researchCompany or unicyciveShire international licensingUnicycive therapeutics incExchange commissionNational kidney foundationLanthanum carbonateAdditional poster highlights key featuresRenal dieticiansSpring clinicalClinical meetingChief executive officerNew drug application

Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that multiple presentations will be delivered on the Company’s product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden. Shalabh Gupta, MD, Chief Execu

United statesUnited kingdomSatya medicherlaShalabh guptaExchange commissionEuropean renal associationDrug administrationUnicycive therapeutics incCompany or unicyciveReason researchShire international licensingRenal associatesMoral administrationChief executive officerUrinary phosphorous reductionComparative study

Unicycive Therapeutics to Present Two Posters on

New Data to be Presented on the Bioequivalence Study for OLC.

United statesLong beachShalabh guptaVandana mathurPnational kidney foundation spring clinical meetingShire international licensingCompany or unicyciveReason researchUnicycive therapeutics incExchange commissionChief executive officerWay crossover studyLanthanum carbonateDietitians perceive phosphate binderLow phosphate diet non complianceTop reasons

Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting - Unicycive Therapeutics (NASDAQ:UNCY)

LOS ALTOS, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company or

Long beachUnited statesShalabh guptaPnational kidney foundation spring clinical meetingExchange commissionReason researchShire international licensingCompany or unicyciveUnicycive therapeutics incChief executive officerOxylanthanum carbonateEnd stage renal diseasePrivate securities litigation reform actRisk factorAnnual reportUnicycive therapeutics